Structure via PubChem · Public domain (PubChem)
voxelotor
Sign in to saveAlso known as GBT-440, GBT440, GBT 440
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It initially appeared to have an acceptable safety profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity noted in clinical trials. It was developed by Global Blood Therapeutics, a subsidiary of Pfizer.
In the Vinony graph
Within Vinony's link graph, voxelotor is referenced by 21 other articles, and connects out to Serpin family G member 1, medication and public domain.
It is catalogued under topics including Drugs developed by Pfizer, Drugs with non-standard legal status and Orphan drugs.
Its subject is documented across 10 Wikipedia language editions.
Key facts
- Drug.image
- File:Voxelotor skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Oxbryta
- Drug.MedlinePlus
- a620011
- Drug.DailyMedID
- Voxelotor
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- B06
- Drug.ATC_suffix
- AX03
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1446321-46-5
- Drug.PubChem
- 71602803
- Drug.DrugBank
- DB14975
- Drug.ChemSpiderID
- 37999268
- Drug.UNII
- 3ZO554A4Q8
- Drug.KEGG
- D11330
- Drug.ChEMBL
- 4101807
- Drug.synonyms
- GBT440, GBT-440
via Wikipedia infobox
Chemical data
- Formula
- C19H19N3O3
- Molecular weight
- 337.4 g/mol
- IUPAC name
- 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)-3-pyridinyl]methoxy]benzaldehyde
- SMILES
- CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
- InChIKey
- FWCVZAQENIZVMY-UHFFFAOYSA-N
- XLogP
- 2.7
- Polar surface area
- 77.2 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- idiopathic pulmonary fibrosis, liver disease, kidney disease, acute lung injury
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 337.14264146799997
- Has use
- medication
Show 3 more facts
- canonical SMILES
- CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O
- chemical formula
- C₁₉H₁₉N₃O₃
- Commons category
- Voxelotor
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
5 sectionsContents
- Side effects
- History
- Society and culture
- Legal status
- References
{{Infobox drug | image = File:Voxelotor skeletal.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Oxbryta | Drugs.com = | MedlinePlus = a620011 | DailyMedID = Voxelotor | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATC_prefix = B06 | ATC_suffix = AX03 | ATC_supplemental =
Excerpted from Wikipedia’s “voxelotor” article, available under the CC BY-SA 4.0 licence.